Synchron's brain-machine interface implant is delivered via catheter, which may reduce the risk of device rejection. () Synchron completed a $10 million Series A round, which will bankroll a ...

- New feature includes AI-driven emotion and language predictions for users in real-time, hands-free without the need for eye tracker or voice control NEW YORK--(BUSINESS WIRE)--Synchron, the ...

New York-based Synchron, a brain-computer interface (BCI) company, has released a video showing an ALS patient using an iPad controlled entirely by thought in what it says is the "first-ever public ...

Thanks to the success of an initial safety trial for an implantable device that can translate the brain’s electrical impulses into readable signals, we’re a step closer to being able to text—or ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain interface platform company, today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm ...

Aug 19 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain ...

Sorrento Therapeutics Inc. has divulged antibody-drug conjugates comprising antibodies targeting HER2 covalently linked to exatecan through a linker. They are ...

New York | The private investment vehicles of billionaires Bill Gates and Jeff Bezos have invested in Australia’s New York-based brain-computer interface company, Synchron, a leading competitor to ...

In an industry-first, the company Synchron and Mount Sinai Hospital in New York have enrolled their first human patient in a U.S. clinical trial called COMMAND to evaluate an endovascular ...

Immuno-oncology company Imugene Ltd. has acquired a worldwide exclusive license to Precision Biosciences Inc.’s allogeneic CD19 CAR T-cell therapy program in a... With a U.S. biotech identified as One ...